Qiagen Downgraded by Investment Firm Macquarie | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citing increasing competition in the human papillomavirus testing space and possible austerity measures by the US government, investment firm Macquarie downgraded Qiagen's shares and revised revenue and EPS estimates on Wednesday.

Macquarie also lowered the target price on Qiagen's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.